+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06090539

Evaluating BMS-986458 Alone and With Anti-lymphoma Agents in RelapsedRefractory Non-Hodgkin Lymphoma A Phase 12 Open-Label Dose-Finding Study

Led by Bristol-Myers Squibb · Updated on 2026-10-23

460

Participants Needed

76

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a drug designed to target B-cell lymphoma 6 BCL6, in participants with relapsed or refractory non-Hodgkin lymphoma. This study also assesses BMS-986458 alone and in combination with other anti-lymphoma treatments. The trial is a phase 12, multi-center, open-label study sponsored by Bristol-Myers Squibb. Participants receive BMS-986458 either as a single agent or combined with anti-lymphoma drugs such as Rituximab, GlofitamabObinutuzumab, Mosunetuzumab, Epcoritamab, or Golcadomide, administered at specified doses on scheduled days. The study includes several experimental parts evaluating these different treatment regimens. The goal is to find appropriate dosing and assess the safety and biological effects of these treatments. During the study, participants undergo regular monitoring for adverse events, including serious and dose-limiting toxicities, for up to 2 years and 1 month. Researchers also evaluate treatment responses using the Lugano criteria for lymphoma, with follow-up assessments extending up to 3 years to track responses, progression-free survival, and overall survival. Participants will have clinical evaluations and laboratory tests throughout their involvement, which may last several years depending on the outcome measures being assessed.

CONDITIONS

Brief Title

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here